BioSpace News Archive

Zimmer Biomet Holdings, Inc.Zimmer Biomet Holdings, Inc. reported financial results for the quarter ended September 30, 2021.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced financial results for the third quarter ended September 30, 2021 and highlighted recent activity.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced financial results for the third quarter of 2021 and provided a general business update.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT7480, a novel, fully synthetic Bicycle tumor-targeted immune cell agonist™ targeting Nectin-4 and agonizing CD137.

LAVA Therapeutics N.V., a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, announced that Stephen Hurly, president and chief executive officer at LAVA, will participate in a virtual fireside chat for the 12th Annual Jefferies London Healthcare Conference taking place from Nov. 16-19, 2021.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, announced that seven abstracts will be presented at the 14th International Congress of Inborn Errors of Metabolism 2021 being held November 21-23, 2021.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, reported financial results for the third quarter ended September 30, 2021 and provided a business update.

iSpecimen Inc., an online marketplace for human biospecimens, reported its financial results for the three and nine-month periods ended September 30, 2021.

Protagonist Therapeutics, Inc. announced that two abstracts highlighting updated data from its Phase 2 study of rusfertide in polycythemia vera have been selected for oral presentations at the American Society of Hematology 2021 Annual Meeting taking place December 11-14, 2021.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that Thierry Chauche will become Chief Financial Officer effective December 1, 2021 and Andrew Drechsler will be retiring, following a career of nearly 30 years in the financial and life sciences industry, most notably, the past four years at Provention Bio.